케이바이오
Financials
Valuation Metrics
케이바이오's Market Cap is ₩144B. At end of 2025 it was ₩312B. Ranked #2359 of 2,410 in KR market (top 98%), #1590 of 1,631 on KOSDAQ (top 97%), #106 of 113 in Consumer Durables & Apparel (top 94%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 14.37B KRW | KR#2,359/2,410 Sec#106/113 |
| Revenue | 74.08B KRW | KR#1,589/2,410 Sec#88/113 |
| Net Income | -41.72B KRW | KR—/2,410 Sec—/113 |
| Total Assets | 74.37B KRW | KR#1,976/2,410 Sec#99/113 |
| Net Assets | 63.19B KRW | KR#1,754/2,410 Sec#88/113 |
| Employees | 33 | KR#2,172/2,410 Sec#104/113 |
| Value | ||
| P/B | 0.23x | KR#248/2,410 Sec#30/113 |
| P/S | 0.19x | KR#425/2,410 Sec#35/113 |
| FCF Yield | 56.79% | KR#79/2,410 Sec#4/113 |
| Profitability | ||
| ROE | -66.03% | KR#2,303/2,410 Sec#109/113 |
| ROA | -56.10% | KR#2,363/2,410 Sec#113/113 |
| Op. Margin | 1.19% | KR#1,483/2,410 Sec#68/113 |
| Revenue Growth | -10.52% | KR#1,931/2,410 Sec#90/113 |
| Financial Health | ||
| Debt Ratio | 17.69% | KR#313/2,410 Sec#19/113 |
| FCF | 8.16B KRW | KR#768/2,410 Sec#39/113 |
| Cash | 2.46B KRW | KR#2,198/2,410 Sec#101/113 |
| Current Ratio | 6.08x | KR#211/2,410 Sec#10/113 |
| Performance | ||
| 1Y Return | -56.98% | KR#2,022/2,410 Sec#94/113 |
| 1M Return | -30.71% | KR#2,148/2,410 Sec#105/113 |
| From 52W High | -79.82% | KR#2,272/2,410 Sec#103/113 |
| 1Y MDD | -78.49% | KR#2,230/2,410 Sec#101/113 |
| Trading | ||
| Volume | 25,381 shares | KR#1,980/2,410 Sec#78/113 |
| Trading Value | 72.6M KRW | KR#2,031/2,410 Sec#81/113 |
| Foreign Own. | 4.02% | KR#1,043/2,410 Sec#40/113 |
| Per Share | ||
| EPS | -8,058 KRW | KR—/2,410 Sec—/113 |
| BPS | 12,204 KRW | KR#845/2,410 Sec#49/113 |
Company Info
K-Bio, established in 1997, expanded its business by acquiring CureBio's distribution division, adding a bio-distribution segment. The company operates two main businesses: distributing life science equipment and reagents, and developing video security equipment and ICT solutions. Leveraging agency contracts with global firms, K-Bio supplies products to universities and hospitals across Seoul and Gyeonggi. The company is actively developing and launching new IoT-based ICT products, including integrated control solutions and GIS MAP systems, from its headquarters in Gangdong-gu, Seoul.